Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ESMO

- PMLiVE

NICE turns down diabetes and ovarian cancer drugs for NHS use

Disappointment for BMS/AZ’s Forxiga and Roche’s Avastin

Roche - Basel

Roche delivers solid sales gain in 2012

New cancer products, such as Perjeta and Zelboraf, help growth

- PMLiVE

Succinct forms market access partnership with Royal Marsden

Agency aims is to tackle non-financial issues relating to new medicines

- PMLiVE

Merck KGaA starts third phase III trial for cancer hope TH-302

Unique method of action to target cells with low oxygen levels

- PMLiVE

Roche’s Avastin gains new US colon cancer approval

Patients can continue to use drug once disease progresses

Max Brady: ‘If I could change one thing…’

The Managing Director of Litmus MME explains what he would improve within the industry

- PMLiVE

Shire launches ADHD and You educational website

Resource designed for patients, carers and HCPs

- PMLiVE

India could hit Roche and BMS with compulsory licences

Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration

Daiichi Sankyo logo

Daiichi, ArQule cancer drug tivantinib flunks another trial

Fails to meet endpoint in colorectal cancer study

- PMLiVE

Janssen’s Zytiga approved for earlier use in Europe

Prostate cancer drug now licensed for use before chemotherapy

EISAI

Eisai’s farletuzumab fails ovarian cancer trial

Unable to improve progression-free survival

- PMLiVE

Nexavar shows promise in thyroid cancer

Potential new indication for Bayer/Onyx drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links